<DOC>
	<DOCNO>NCT02148380</DOCNO>
	<brief_summary>The result fastact2 show chemotherapy plus erlotinib significantly prolong PFS OS patient NSCLC . However , outcome combination therapy similar report several trial single-agent EGFR TKIs . So optimal first-line treatment patient harbor sensitive EGFR mutation ? The investigator need head-to-head study reply .</brief_summary>
	<brief_title>Combination Chemotherapy Gefitinib First-line Treatment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Signed informed consent 2 . Age &gt; =18 year 3 . Histologically document , unresectable , inoperable , locally advanced , recurrent metastatic Stage IV NonSmall Cell Lung Cancer ( NSCLC ) 4 . A cytologic diagnosis acceptable ( i.e. , FNA pleural fluid cytology ) 5 . Measurable nonmeasurable disease 6 . Able comply study followup procedure Evidence small cell , carcinoid , mixed small cell/nonsmall cell histology Malignancies within 3 year except adequately treat carcinoma situ cervix basal squamous cell skin cancer Symptomatic untreated brain metastasis Prior systemic chemotherapy NSCLC Unstable systemic disease , include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within 6 month prior Day 1 , serious cardiac arrhythmia require medication ( patient chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia , eligible ) History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication Gastrointestinal tract disease result inability take oral medication requirement intravenous ( IV ) alimentation , prior surgical procedure affect absorption Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Lung adenocarcinoma , EGFR mutation , chemotherapy , gefitinib</keyword>
</DOC>